AIM: To investigate the clinical efficacy of statins in the treatment of patients with migraine and hyperlipidemia. METHODS: A retrospective analysis was performed on the clinical data of 118 patients with hyperlipidemia and migraine diagnosed and treated in our hospital from September 9, 2016 to August 2021. According to hyperlipidemia and previous cardio-cerebral vascular disease history, Atorvastatin and Rosuvastatin were given different doses respectively, and the improvement of blood lipid index was compared. The average VAS, headache frequency and headache frequency at 3 months after treatment were compared with those before treatment.Comparison of the same indicator within 3 months. RESULTS: The total effective rate of blood lipid control in each group was satisfactory, which was 91.7%, 94.1%, 88.2% and 92.9%, respectively. Group B and Group D had a slightly higher control rate in the high-dose statin group compared with similar groups A and C. After treatment, all four groups of patients had different degrees of migraine reduction, and group A was the lowest group with response rate of 36.1%, and group D was the highest group with response rate of 53.6%. The average VAS of pain in the high-dose statin group was greater and the pain relief was more pronounced. There was no significant statistical difference between the groups in the pain onset of VAS score reduction by 50% and the frequency of attacks by 50%, P>0.05. CONCLUSION: The use of statins in the treatment of patients with hyperlipidemia and migraine has satisfactory control of hyperlipidemia, and there is no significant difference in statin categories. The migraine symptoms associated with them can be relieved to varying degrees, and some patients have reliable clinical effects.